Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial

TACT Trial Management Group, Paul Ellis, Peter Barrett-Lee, Lindsay Johnson, David Cameron, Andrew Wardley, Susan O'Reilly, Mark Verrill, Ian Smith, John Yarnold, Robert Coleman, Helena Earl, Peter Canney, Chris Twelves, Christopher Poole, David Bloomfield, Penelope Hopwood, Stephen Johnston, Mitchell Dowsett, John M S BartlettIan Ellis, Clare Peckitt, Emma Hall, Judith M Bliss

Research output: Contribution to journalArticlepeer-review

Abstract / Description of output

Incorporation of a taxane as adjuvant treatment for early breast cancer offers potential for further improvement of anthracycline-based treatment. The UK TACT study (CRUK01/001) investigated whether sequential docetaxel after anthracycline chemotherapy would improve patient outcome compared with standard chemotherapy of similar duration.
Original languageEnglish
Pages (from-to)1681-92
Number of pages12
JournalThe Lancet
Volume373
Issue number9676
DOIs
Publication statusPublished - 2009

Fingerprint

Dive into the research topics of 'Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial'. Together they form a unique fingerprint.

Cite this